Vitrakvi(larotrectinib)
Vitrakvi (larotrectinib) is a small molecule pharmaceutical. Larotrectinib was first approved as Vitrakvi on 2018-11-26. It is used to treat neoplasm drug resistance and neoplasm metastasis in the USA. It has been approved in Europe to treat abdominal neoplasms. It is known to target high affinity nerve growth factor receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Vitrakvi
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vitrakvi | New Drug Application | 2023-11-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neoplasm metastasis | EFO_0009708 | D009362 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LAROTRECTINIB SULFATE, VITRAKVI, BAYER HEALTHCARE | |||
| 2025-11-26 | ODE-215, ODE-220, ODE-221 | ||
LAROTRECTINIB SULFATE, VITRAKVI, BAYER HLTHCARE | |||
| 2025-11-26 | ODE-215, ODE-220, ODE-221 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Larotrectinib Sulfate, Vitrakvi, Bayer Healthcare | |||
| 10045991 | 2037-04-04 | U-2473 | |
| 10137127 | 2037-04-04 | DP | |
| 10668072 | 2037-04-04 | DP | |
| 11191766 | 2037-04-04 | U-2471 | |
| 11484535 | 2037-04-04 | U-2470 | |
| 10799505 | 2036-08-15 | DS, DP | |
| 9782414 | 2035-11-16 | U-2471, U-2475 | |
| 10172861 | 2035-11-16 | DS, DP | |
| 8513263 | 2029-12-23 | DS, DP | |
| 8865698 | 2029-10-21 | U-2469 | |
| 9127013 | 2029-10-21 | DS, DP | |
| 9447104 | 2029-10-21 | U-2470 | |
| 9676783 | 2029-10-21 | U-2469 | |
| 10005783 | 2029-10-21 | U-2472 | |
| 10047097 | 2029-10-21 | U-2474 | |
| 10774085 | 2029-10-21 | U-2470 | |
| Larotrectinib Sulfate, Vitrakvi, Bayer Hlthcare | |||
| 10285993 | 2035-11-16 | U-2470 | |
| 10813936 | 2035-11-16 | U-2987 | |
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 3 | — | 1 | — | 4 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | 3 | — | 1 | — | 4 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 10 | — | — | 5 | 16 |
| Recurrence | D012008 | — | — | — | 3 | — | — | 1 | 4 |
| Lymphoma | D008223 | — | C85.9 | — | 4 | — | — | — | 4 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 3 | — | — | — | 4 |
| Sarcoma | D012509 | — | — | 1 | 2 | — | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | — | 3 | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 3 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | — | 3 | — | — | — | 3 |
| Nervous system neoplasms | D009423 | — | — | — | 3 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | — | 2 | — | — | — | 2 |
Show 46 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Larotrectinib |
| INN | larotrectinib |
| Description | Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 1223403-58-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3889654 |
| ChEBI ID | — |
| PubChem CID | 46188928 |
| DrugBank | DB14723 |
| UNII ID | PF9462I9HX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NTRK1
NTRK1
Organism
Homo sapiens
Gene name
NTRK1
Gene synonyms
MTC, TRK, TRKA
NCBI Gene ID
Protein name
high affinity nerve growth factor receptor
Protein synonyms
gp140trk, Neurotrophic tyrosine kinase receptor type 1, neurotrophic tyrosine kinase, receptor, type 1, Oncogene TRK, p140-TrkA, Trk-A, TRK1-transforming tyrosine kinase protein, tropomyosin receptor kinase A, Tropomyosin-related kinase A, Tyrosine kinase receptor, Tyrosine kinase receptor A
Uniprot ID
Mouse ortholog
Ntrk1 (18211)
high affinity nerve growth factor receptor (Q3UFB7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,543 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
660 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use